Characterization of the human cysteinyl leukotriene CysLT1 receptor
暂无分享,去创建一个
Jilly F. Evans | C. Austin | B. Connolly | C. Caskey | R. Stocco | A. Ford-hutchinson | S. Kargman | G. O'neill | M. Abramovitz | D. Im | Elizabeth M. Hosfield | K. Metters | N. Coulombe | K. Lynch | A. Châteauneuf | N. Sawyer | David Williams | Z. Zeng | D. Figueroa | S. Hooks | G. Greig | David L. Williams | Qingyun Liu | Chang Bai | Christopher P. Austin | A. Châteauneuf | Brett Connolly
[1] R. Stocco,et al. An automated aequorin luminescence-based functional calcium assay for G-protein-coupled receptors. , 1999, Analytical biochemistry.
[2] R. Doms,et al. Leukotriene Binding, Signaling, and Analysis of HIV Coreceptor Function in Mouse and Human Leukotriene B4Receptor-transfected Cells* , 1999, The Journal of Biological Chemistry.
[3] L. F. Kolakowski,et al. Molecular Characterization and Expression of Cloned Human Galanin Receptors GALR2 and GALR3 , 1998, Journal of neurochemistry.
[4] L Hendeles,et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. , 1998, The New England journal of medicine.
[5] R. Dockhorn,et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. , 1998, Archives of internal medicine.
[6] J. Bernstein,et al. Montelukast for Chronic Asthma in 6- to 14-Year-Old Children A Randomized, Double-blind Trial , 1998 .
[7] A. Ford-hutchinson,et al. Characterization of the recombinant human prostanoid DP receptor and identification of L‐644,698, a novel selective DP agonist , 1998, British journal of pharmacology.
[8] T. Macdonald,et al. Characterization of a receptor subtype-selective lysophosphatidic acid mimetic. , 1998, Molecular pharmacology.
[9] Takao Shimizu,et al. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis , 1997, Nature.
[10] S. Suissa,et al. Effectiveness of the Leukotriene Receptor Antagonist Zafirlukast for Mild-to-Moderate Asthma , 1997, Annals of Internal Medicine.
[11] W. Busse,et al. Results of the first U.S. double-blind, placebo-controlled, multicenter clinical study in asthma with pranlukast, a novel leukotriene receptor antagonist. , 1997, The Journal of asthma : official journal of the Association for the Care of Asthma.
[12] M. Lerner,et al. Melanophore pigment dispersion responses to agonists show two patterns of sensitivity to inhibitors of cAMP‐dependent protein kinase and protein kinase C , 1996, Journal of cellular physiology.
[13] J. Evans,et al. Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist. , 1995, Canadian journal of physiology and pharmacology.
[14] J. Drazen,et al. Prostanoid and leukotriene receptors: a progress report from the IUPHAR working parties on classification and nomenclature. , 1995, Advances in prostaglandin, thromboxane, and leukotriene research.
[15] I. Rodger,et al. Leukotriene D4-induced increases in cytosolic calcium in THP-1 cells: dependence on extracellular calcium and inhibition with selective leukotriene D4 receptor antagonists. , 1994, The Journal of pharmacology and experimental therapeutics.
[16] M. Potenza,et al. Functional expression and characterization of human D2 and D3 dopamine receptors , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[17] K. Lynch,et al. Responses to sphingosine-1-phosphate in X. laevis oocytes: similarities with lysophosphatidic acid signaling. , 1993, The American journal of physiology.
[18] R. Zamboni,et al. Photoaffinity labeling of the leukotriene D4 receptor in guinea pig lung. , 1993, The Journal of biological chemistry.
[19] D. Nicholson,et al. Characterization of the leukotriene D4 receptor in dimethylsulphoxide-differentiated U937 cells: comparison with the leukotriene D4 receptor in human lung and guinea-pig lung. , 1993, European journal of pharmacology.
[20] C. Labat,et al. A second cysteinyl leukotriene receptor in human lung. , 1992, The Journal of pharmacology and experimental therapeutics.
[21] Robert A. Lewis,et al. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. , 1990, The New England journal of medicine.
[22] A. Ford-hutchinson,et al. Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist. , 1989, Canadian journal of physiology and pharmacology.
[23] D. Lipman,et al. Improved tools for biological sequence comparison. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[24] T. Jones,et al. Effects of l‐serine borate on antagonism of leukotriene C4‐induced contractions of guinea‐pig trachea , 1987, British journal of pharmacology.
[25] P. Piper. Formation and actions of leukotrienes. , 1984, Physiological reviews.
[26] Bengt Samuelsson,et al. Leukotrienes are potent constrictors of human bronchi , 1980, Nature.